SynthesisJournal of gastrointestinal cancer2026
Pretransplant Systemic Therapies for Hepatocellular Carcinoma: A Systematic Review of Posttransplant Outcomes.
Synthesis in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSystemic therapies are increasingly being explored as strategies to downstage or bridge patients with unresectable hepatocellular cancer (HCC) to liver transplantation (LT). This systematic review aimed to assess pooled survival and posttransplant outcomes in patients receiving such therapies.
methodsWe searched PubMed, Embase and Medline through September 2025 to identify interventional and observational studies on adult patients with HCC treated with any systemic regimen before LT. Outcomes included 1- and 3-year overall survival (OS) and proportions of recurrence, mortality and rejection. We assessed risk of bias and quality using established tools and presented pooled cumulative incidence proportions and prevalences in forest plots.
resultsFourteen studies were included, encompassing 412 patients, with up to 26 possible overlaps. After LT, the pooled OS was 88% at 1 year (95%CI: 81% to 93%) and 76% at 3 years (95%CI: 65% to 85%). Acute rejection occurred in 21% patients overall (95%CI: 12% to 34%) and mortality in 17% (95%CI: 10% to 26%). HCC recurrence concerned 23% of patients (95%CI: 16% to 32%) at a median time-to-recurrence of 13.5 months (95%CI: 4.7 to 22.4).
conclusionWe pooled posttransplant cumulative incidence proportions in HCC patients who received systemic therapy before LT, providing reference estimates to help interpret outcomes across HCC stages.
Indexed as
Identifiers
41689676What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.